Free · 13,587 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Eye, Ear & Vision

Intense pulsed light as a multi-target intervention paradigm for refractory ocular surface diseases: a review

Overall, IPL therapy represents a promising but evolving treatment strategy for refractory OSDs.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

This review summarizes proposed mechanisms, clinical uses, and protocols of intense pulsed light for refractory ocular surface diseases such as meibomian gland dysfunction and Demodex blepharitis. The authors report that case series and clinical studies showed symptom and gland improvements, particularly when combined with other therapies. They note that mechanisms are incompletely established and that randomized controlled trials and long-term safety data remain limited.

Who or what was studied
Patients with refractory ocular surface diseases, including meibomian gland dysfunction, Demodex-associated blepharitis, ocular rosacea, recurrent chalazion, and allergic conjunctivitis
Limits stated in the abstract
The review notes limited high-quality randomized controlled trials, limited long-term safety data, and variable responses across disease phenotypes and treatment parameters.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Ocular surface diseases (OSDs) are a heterogeneous group of disorders characterized by overlapping inflammatory, vascular, microbial, neuroimmune, and meibomian gland abnormalities that contribute to the onset and persistence of ocular surface symptoms and signs. Conventional symptom-directed therapies do not adequately alleviate refractory meibomian gland dysfunction, Demodex-associated blepharitis, ocular rosacea, recurrent chalazion, and allergic conjunctivitis. Recent evidence suggests that these conditions may share convergent pathological features, including chronic inflammation, abnormal lid-margin vascularity, and microbial or parasitic imbalance. Intense pulsed light (IPL), which was initially used for vascular and inflammatory disorders in dermatology, has emerged as a potential physical therapy that acts through several proposed mechanisms in patients with selected refractory OSDs, including photothermal liquefaction of inspissated meibum, coagulation of abnormal vessels, reduction of Demodex and microbial burden, modulation of inflammatory responses, and possible effects on neuroimmune signaling; however, these mechanisms remain incompletely established. Case series and clinical studies have reported improvements in ocular symptoms, tear film stability, meibomian gland function and drainage, lid-margin inflammation, and chalazion or lesion resolution, particularly when IPL is combined with meibomian gland expression or other adjunctive therapies. However, treatment responses vary across disease phenotypes and standardized treatment parameters, long-term safety data, and high-quality randomized controlled trials remain limited. Anatomical factors, disease severity, glandular structure, and inflammatory status may also influence therapeutic outcomes. Overall, IPL therapy represents a promising but evolving treatment strategy for refractory OSDs. This review summarizes the current knowledge regarding the proposed mechanisms, clinical applications, treatment protocols, limitations, and future directions and provides updated perspectives for the rational use of IPL in OSD management.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Inflammation. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies